{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:47:53Z","timestamp":1761587273945,"version":"build-2065373602"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.intimp.2022.109175","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T02:19:14Z","timestamp":1660702754000},"page":"109175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Recent advances in the vaccine development for the prophylaxis of SARS Covid-19"],"prefix":"10.1016","volume":"111","author":[{"given":"Vipul","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabodh Chander","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2022.109175_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tmrv.2020.02.003","article-title":"Coronavirus disease 2019: coronaviruses and blood safety","volume":"34","author":"Chang","year":"2020","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.intimp.2022.109175_b0010","doi-asserted-by":"crossref","unstructured":"K. McIntosh, Coronaviruses: a comparative review. Current topics in microbiology and immunology\/Ergebnisse der Mikrobiologie und Immunit\u00e4tsforschung, 1974, 85\u2013129.","DOI":"10.1007\/978-3-642-65775-7_3"},{"issue":"1","key":"10.1016\/j.intimp.2022.109175_b0015","first-page":"8","article-title":"Coronavirus: a mini-review","volume":"6","author":"Syed","year":"2020","journal-title":"Int. J. Curr. Res. Med. Sci."},{"key":"10.1016\/j.intimp.2022.109175_b0020","unstructured":"Centers-for-Disease-Control-and-Prevention. Human Coronavirus Types. 2020. Available from: <https:\/\/www.cdc.gov\/coronavirus\/types.html>."},{"key":"10.1016\/j.intimp.2022.109175_b0025","doi-asserted-by":"crossref","unstructured":"L. van der Hoek, Human coronaviruses: what do they cause? Antivir. Ther. 12 (4 Pt B) (2007) 651\u2013658.","DOI":"10.1177\/135965350701200S01.1"},{"issue":"4","key":"10.1016\/j.intimp.2022.109175_b0030","first-page":"328","article-title":"COVID-19: The first documented coronavirus pandemic in history","volume":"43","author":"Liu","year":"2020","journal-title":"Biome. J."},{"issue":"19","key":"10.1016\/j.intimp.2022.109175_b0035","article-title":"Genomic characterization of a novel SARS-CoV-2","volume":"1","author":"Khailany","year":"2020","journal-title":"Gene Rep."},{"key":"10.1016\/j.intimp.2022.109175_b0040","doi-asserted-by":"crossref","unstructured":"H. Ouassou, L. Kharchoufa, M. Bouhrim, N.E. Daoudi, H. Imtara, N. Bencheikh, A. ELbouzidi, M. Bnouham, The pathogenesis of coronavirus disease 2019 (COVID-19): evaluation and prevention, J. Immunol. Res. 2020 (2020).","DOI":"10.1155\/2020\/1357983"},{"issue":"4","key":"10.1016\/j.intimp.2022.109175_b0045","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41591-020-0822-7","article-title":"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China","volume":"26","author":"Wu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2022.109175_b0050","doi-asserted-by":"crossref","unstructured":"I. Madabhavi, M. Sarkar, N. Kadakol, COVID-19: a review, Monaldi Arch. Chest Dis. 90 (2) (2020).","DOI":"10.4081\/monaldi.2020.1298"},{"key":"10.1016\/j.intimp.2022.109175_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.19719","article-title":"Long-term health consequences of COVID-19","author":"Del Rio","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.intimp.2022.109175_b0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/ph14050406","article-title":"COVID-19 vaccines: a review of the safety and efficacy of current clinical trials","volume":"14","author":"Yan","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.intimp.2022.109175_b0065","doi-asserted-by":"crossref","first-page":"P19","DOI":"10.1164\/rccm.2020C1","article-title":"Diagnosis and management of COVID-19 disease","volume":"201","author":"Jamil","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2022.109175_b0070","doi-asserted-by":"crossref","unstructured":"H.R. G\u00dcNER, \u0130. Hasano\u011flu, F. Akta\u015f, COVID-19: prevention and control measures in community, Turkish J. Med. Sci. 50 (SI-1) (2020) 571\u2013177.","DOI":"10.3906\/sag-2004-146"},{"issue":"10","key":"10.1016\/j.intimp.2022.109175_b0075","first-page":"41","article-title":"Dental caries vaccine\u2013a change","volume":"2","author":"Yesh","year":"2018","journal-title":"Acta Sci. Dental Sci."},{"key":"10.1016\/j.intimp.2022.109175_b0080","first-page":"2017","article-title":"Vaccination coverage and associated factors among children aged 12\u201323 months in debre markos town, Amhara regional state, Ethiopia","volume":"1","author":"Gualu","year":"2017","journal-title":"Adv. Public Health."},{"issue":"2","key":"10.1016\/j.intimp.2022.109175_b0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1385\/MB:21:2:129","article-title":"The development and use of vaccine adjuvants","volume":"21","author":"Edelman","year":"2002","journal-title":"Mol. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0090","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/jcpt.13516","article-title":"Vaccination terminology: A revised glossary of key terms including lay person\u2019s definitions","volume":"47","author":"Brennan","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"issue":"7349","key":"10.1016\/j.intimp.2022.109175_b0095","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/bmj.324.7349.1315","article-title":"New vaccine development","volume":"324","author":"Poland","year":"2002","journal-title":"BMJ"},{"issue":"6494","key":"10.1016\/j.intimp.2022.109175_b0100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.abc5312","article-title":"A strategic approach to COVID-19 vaccine R&D","volume":"368","author":"Corey","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.109175_b0105","unstructured":"Centers-for-Disease-Control-and-Prevention. Developing COVID-19 Vaccines. 2021. Available from: <https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/distributing\/steps-ensure-safety.html>."},{"issue":"4","key":"10.1016\/j.intimp.2022.109175_b0110","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1331\/JAPhA.2009.09007","article-title":"Vaccine supply, demand, and policy: a primer","volume":"49","author":"Muzumdar","year":"2009","journal-title":"Journal of the American Pharmacists Association"},{"issue":"13\u201314","key":"10.1016\/j.intimp.2022.109175_b0115","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0264-410X(00)00354-6","article-title":"Use of live bacterial vaccine vectors for antigen delivery: potential and limitations","volume":"19","author":"Medina","year":"2001","journal-title":"Vaccine."},{"issue":"5","key":"10.1016\/j.intimp.2022.109175_b0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biologicals.2014.07.003","article-title":"Adventitious agents in viral vaccines: lessons learned from 4 case studies","volume":"42","author":"Petricciani","year":"2014","journal-title":"Biologicals"},{"issue":"8","key":"10.1016\/j.intimp.2022.109175_b0125","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41591-021-01459-7","article-title":"Understanding COVID-19 vaccine hesitancy","volume":"27","author":"Machingaidze","year":"2021","journal-title":"Nat. Med."},{"issue":"10278","key":"10.1016\/j.intimp.2022.109175_b0130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2022.109175_b0135","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.celrep.2019.10.105","article-title":"Characterization of antigenic MHC-class-I-restricted t cell epitopes in the glycoprotein of ebolavirus","volume":"29","author":"Powlson","year":"2019","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.intimp.2022.109175_b0140","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jceh.2020.06.003","article-title":"COVID-19 vaccines: a race against time in the middle of death and devastation!","volume":"10","author":"Khuroo","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"35","key":"10.1016\/j.intimp.2022.109175_b0145","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1016\/j.vaccine.2011.06.051","article-title":"The gold industry standard for risk and cost of drug and vaccine development revisited","volume":"29","author":"Pronker","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2022.109175_b0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14573\/altex.1509081","article-title":"Animal use for science in Europe. Alternatives to animal experimentation","volume":"32","author":"Daneshian","year":"2015","journal-title":"ALTEX"},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.intimp.2022.109175_b0160","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nbt0596-591","article-title":"Vaccine R&D success rates and development times","volume":"14","author":"Struck","year":"1996","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109175_b0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1257\/089533002320950984","article-title":"Pharmaceuticals and the developing world","volume":"16","author":"Kremer","year":"2002","journal-title":"J. Econ. Perspectives"},{"key":"10.1016\/j.intimp.2022.109175_b0170","unstructured":"Organization, W.H., DRAFT landscape of COVID-19 candidate vaccines. World. 2020."},{"key":"10.1016\/j.intimp.2022.109175_b0175","unstructured":"FDA, Investigational new drug (IND) Application, 2020."},{"key":"10.1016\/j.intimp.2022.109175_b0180","unstructured":"Agency, E.M., Clinical Trial Regulation, 2019."},{"issue":"6","key":"10.1016\/j.intimp.2022.109175_b0185","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.31925\/farmacia.2019.6.12","article-title":"Reactogenicity and medically attended adverse events following hexavalent vaccination: an observational prospective study","volume":"67","author":"Bulik","year":"2019","journal-title":"Farmacia"},{"issue":"2","key":"10.1016\/j.intimp.2022.109175_b0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.31925\/farmacia.2020.2.5","article-title":"Adverse events following measles-mumps-rubella vaccination. A prospective observational study","volume":"68","author":"Bucsa","year":"2020","journal-title":"Farmacia"},{"key":"10.1016\/j.intimp.2022.109175_b0195","first-page":"1","article-title":"COVID-19 vaccines: ethical framework concerning human challenge studies","author":"Calina","year":"2020","journal-title":"DARU J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2022.109175_b0200","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109175_b0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/10_2019_107","article-title":"Advances in vaccines","author":"Mao","year":"2019","journal-title":"Curr. Appl. Pharm. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109175_b0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1377\/hlthaff.2020.01620","article-title":"An overview of vaccine development, approval, and regulation, with implications for COVID-19: analysis reviews the food and drug administration's critical vaccine approval role with implications for COVID-19 vaccines","volume":"40","author":"Kesselheim","year":"2021","journal-title":"Health Aff."},{"issue":"Special Issue","key":"10.1016\/j.intimp.2022.109175_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18678\/dtfd.890089","article-title":"A review of the progress of COVID-19 vaccine development","volume":"23","author":"Ullah","year":"2021","journal-title":"Duzce Med. J."},{"issue":"5","key":"10.1016\/j.intimp.2022.109175_b0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jama.2020.12461","article-title":"The development of COVID-19 vaccines: safeguards needed","volume":"324","author":"Lurie","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0225","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/tbed.13804","article-title":"Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development","volume":"68","author":"Begum","year":"2021","journal-title":"Transboundary Emerg. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.109175_b0230","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.intimp.2022.109175_b0235","unstructured":"Development and Licensure of Vaccines to Prevent COVID-19. Available from: <https:\/\/www.fda.gov\/ media\/139638\/download> (FDA, 2020)."},{"issue":"11","key":"10.1016\/j.intimp.2022.109175_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003001","article-title":"Vaccines: from empirical development to rational design","volume":"8","author":"Rueckert","year":"2012","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0250","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/157489106778777673","article-title":"Advances in the development of inactivated virus vaccines","volume":"1","author":"Stauffer","year":"2006","journal-title":"Recent Pat. Anti-Infect. Drug Discovery"},{"key":"10.1016\/j.intimp.2022.109175_b0255","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1080\/22221751.2020.1737580","article-title":"Timely development of vaccines against SARS-CoV-2","volume":"9","author":"Lu","year":"2020","journal-title":"Emerging Microbes Infect."},{"key":"10.1016\/j.intimp.2022.109175_b0260","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.intimp.2022.109175_b0265","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","article-title":"Structure-based antigen design: a strategy for next generation vaccines","volume":"26","author":"Dormitzer","year":"2008","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.intimp.2022.109175_b0270","doi-asserted-by":"crossref","unstructured":"S. Lu, Editorial overview: vaccines against challenging viral pathogens and new vaccine technology, doi: 10.1016\/j.coviro.2014.04.006. 2014.","DOI":"10.1016\/j.coviro.2014.04.006"},{"issue":"42","key":"10.1016\/j.intimp.2022.109175_b0275","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1016\/j.vaccine.2014.07.074","article-title":"Technology transfer and scale-up of the Flublok\u00ae recombinant hemagglutinin (HA) influenza vaccine manufacturing process","volume":"32","author":"Buckland","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2022.109175_b0280","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg. Infect. Dis."},{"issue":"119","key":"10.1016\/j.intimp.2022.109175_b0285","first-page":"129","article-title":"Animal coronavirus vaccines: lessons for SARS","volume":"1","author":"Saif","year":"2004","journal-title":"Dev. Biol. (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109175_b0290","first-page":"1","article-title":"Optimal control of the COVID-19 pandemic: controlled sanitary deconfinement in Portugal","volume":"11","author":"Silva","year":"2021","journal-title":"Sci. Rep."},{"issue":"4\u20135","key":"10.1016\/j.intimp.2022.109175_b0295","article-title":"Management of COVID-19: Current status and future prospects","volume":"23","author":"Kabir","year":"2021","journal-title":"Microbes Infect."},{"issue":"50","key":"10.1016\/j.intimp.2022.109175_b0300","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.1016\/j.vaccine.2020.10.056","article-title":"India\u2019s cost-effective COVID-19 vaccine development initiatives","volume":"38","author":"Chakraborty","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.109175_b0305","article-title":"Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19","volume":"1258","author":"Saha","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109175_b0310","doi-asserted-by":"crossref","unstructured":"G. Salvatori, L. Luberto, M. Maffei, L. Aurisicchio, L. Aurisicchio, G. Roscilli, G. Roscilli, F. Palombo, E. Marra, E. Marra, SARS-CoV-2 spike protein: an optimal immunological target for vaccines, J. Transl. Med. (2020), doi: 10.1186\/s12967-020-02392-y.","DOI":"10.1186\/s12967-020-02392-y"},{"issue":"2","key":"10.1016\/j.intimp.2022.109175_b0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","volume":"7","author":"Chen","year":"2020","journal-title":"Curr. Tropical Med. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2022.109175_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05007","article-title":"Nucleic acid-based therapy for coronavirus disease 2019","volume":"6","author":"Piyush","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2022.109175_b0325","first-page":"1","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","author":"Chen","year":"2020","journal-title":"Curr. Tropical Med. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0330","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/CMR.8.3.406","article-title":"Nucleic acid vaccines","volume":"8","author":"Vogel","year":"1995","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.intimp.2022.109175_b0335","article-title":"DNA vaccines-how far from clinical use?","volume":"3605","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.109175_b0340","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109175_b0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.22159\/ajpcr.2021.v14i5.41061","article-title":"Current updates on COVID-19 vaccines","volume":"7","author":"Misra","year":"2021","journal-title":"Asian J. Pharma. Clin. Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0350","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4155\/tde-2020-0129","article-title":"An overview of vaccine development for COVID-19","volume":"12","author":"Shahcheraghi","year":"2021","journal-title":"Therapeutic Delivery"},{"issue":"4","key":"10.1016\/j.intimp.2022.109175_b0355","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev Drug Discov."},{"key":"10.1016\/j.intimp.2022.109175_b0360","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kaufman","year":"2016","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.intimp.2022.109175_b0365","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7830","key":"10.1016\/j.intimp.2022.109175_b0370","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109175_b0375","unstructured":"J&J. working on coronavirus vaccine. thepharmaletter 2020. Available from: <https:\/\/www. thepharmaletter.com\/article\/j-j-working-on-coronavirusvaccine>. Accessed 28 Feb 2020. 2020."},{"key":"10.1016\/j.intimp.2022.109175_b0380","unstructured":"ClinicalTrials.gov. National Institutes of Health. Available from: <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02543567>. Accessed February 7, 2020. 2020."},{"key":"10.1016\/j.intimp.2022.109175_b0385","unstructured":"E. C. China coronavirus: Hong Kong researchers have already developed vaccine but need time to test it, expert reveals. South China Morning Post. Available from: <https:\/\/www.scmp.com\/news\/hong-kong\/health-environment\/article\/3047956\/china-coronavirus-hongkong-researchers-have>. Accessed 28 Feb 2020, 2020."},{"key":"10.1016\/j.intimp.2022.109175_b0390","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1586\/erv.12.126","article-title":"Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome","volume":"11","author":"Jiang","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2022.109175_b0395","unstructured":"J. S. Codagenix raises $20 million for a new flu vaccine and other therapies. Tech Crunch. Available from: <https:\/\/techcrunch.com\/2020\/01\/13\/codagenix-raises20-million-for-a-new-flu-vaccine-and-othertherapies\/>. Accessed 28 Feb 2020, 2020."},{"key":"10.1016\/j.intimp.2022.109175_b0400","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109175_b0405","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.109175_b0410","doi-asserted-by":"crossref","unstructured":"Y.-J. Zhang et al., Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial, 2020. Preprint at doi: 10.1101\/2020. 07.31.20161216.","DOI":"10.1101\/2020.07.31.20161216"},{"key":"10.1016\/j.intimp.2022.109175_b0415","unstructured":"Draft Landscape of COVID-19 Candidate Vaccines. Available from: <https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines> (WHO, accessed 26 September 2020)."},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0420","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00907-20","article-title":"Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection?","volume":"11","author":"Fidel","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.intimp.2022.109175_b0425","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1073\/pnas.070525997","article-title":"Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach","volume":"97","author":"Talon","year":"2000","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2022.109175_b0430","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.vaccine.2015.11.054","article-title":"Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets","volume":"34","author":"Broadbent","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.109175_b0435","doi-asserted-by":"crossref","unstructured":"S. Okamura, H. Ebina, Could live attenuated vaccines better control COVID-19? Vaccine 39 (39) (2021) 5719\u20135726.","DOI":"10.1016\/j.vaccine.2021.08.018"},{"issue":"09","key":"10.1016\/j.intimp.2022.109175_b0440","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3855\/jidc.12805","article-title":"Could \u201ctrained immunity\u201d be induced by live attenuated vaccines protect against COVID-19? Review of available evidence","volume":"14","author":"Alsulaiman","year":"2020","journal-title":"J. Infect. Dev. Countries"},{"issue":"1","key":"10.1016\/j.intimp.2022.109175_b0445","doi-asserted-by":"crossref","first-page":"e00298","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and multipathogen viral vector vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109175_b0450","doi-asserted-by":"crossref","first-page":"328","DOI":"10.53854\/liim-2903-3","article-title":"Review of COVID-19 viral vector-based vaccines and COVID-19 variants","volume":"29","author":"Vanaparthy","year":"2021","journal-title":"Le Infezioni in Medicina."},{"key":"10.1016\/j.intimp.2022.109175_b0455","unstructured":"NIH: NIAID, vaccine types | NIH: national institute of allergy and infectious diseases, NIH Natl. Inst. Allergy Infect. Dis. (2019), doi: 10.1016\/0021- 8707(56)90057-0."},{"key":"10.1016\/j.intimp.2022.109175_b0460","unstructured":"World Health Organization, MODULE 2- Types of Vaccine and Adverse Reactions, WHO, 2018, pp. 41\u201342."},{"key":"10.1016\/j.intimp.2022.109175_b0465","doi-asserted-by":"crossref","unstructured":"M. Wang, S. Jiang, Y. Wang, Recent advances in the production of recombinant subunit vaccines in Pichia pastoris, Bioengineered (2016), doi: 10.1080\/21655979.2016.1191707.","DOI":"10.1080\/21655979.2016.1191707"},{"key":"10.1016\/j.intimp.2022.109175_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117956","article-title":"Vaccination strategies to combat novel corona virus SARS-CoV-2","author":"Pandey","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.109175_b0475","unstructured":"World Health Organization, Draft Landscape of COVID-19 Candidate Vaccines - 28th July, Who, 2020."},{"key":"10.1016\/j.intimp.2022.109175_b0480","unstructured":"Available from: <https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/covid-19-vaccine-tracker>."},{"key":"10.1016\/j.intimp.2022.109175_b0485","unstructured":"Available from: <https:\/\/covid19.trackvaccines.org\/vaccines\/>."},{"issue":"11","key":"10.1016\/j.intimp.2022.109175_b0490","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","article-title":"Disappearance of antibodies to SARS-associated coronavirus after recovery","volume":"357","author":"Cao","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109175_b0495","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3201\/eid1310.070576","article-title":"Duration of antibody responses after severe acute respiratory syndrome","volume":"13","author":"Wu","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109175_b0500","article-title":"What reinfections mean for COVID-19","author":"Iwasaki","year":"2020","journal-title":"Lancet. Infect. Dis"},{"issue":"7","key":"10.1016\/j.intimp.2022.109175_b0505","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3390\/jcm9072268","article-title":"Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients","volume":"9","author":"Ko","year":"2020","journal-title":"J Clin Med."},{"issue":"7824","key":"10.1016\/j.intimp.2022.109175_b0510","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/d41586-020-02544-6","article-title":"The coronavirus is mutating\u2014does it matter?","volume":"585","author":"Callaway","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2022.109175_b0515","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109175_b0520","doi-asserted-by":"crossref","unstructured":"L. Zhang, C.B. Jackson, H. Mou, A. Ojha, E.S. Rangarajan, T. Izard, M. Farzan, H. Choe, The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity, bioRxiv, 2020, doi: 10.1101\/2020.06.12.148726.","DOI":"10.1101\/2020.06.12.148726"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:45:53Z","timestamp":1761587153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922006592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":104,"alternative-id":["S1567576922006592"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109175","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the vaccine development for the prophylaxis of SARS Covid-19","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109175"}}